A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Recruiting

Phase 3

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Sponsor:

AbbVie

Code:

NCT04064827

Conditions

Chronic Kidney Disease (CKD)

Secondary Hyperparathyroidism (SHPT)

Eligibility Criteria

Sex: All

Age: 0 - 9

Healthy Volunteers: Not accepted

Interventions

Paricalcitol

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-24. This information was provided to ClinicalTrials.gov by AbbVie on 2025-03-12.